Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches

Reid, A.T.; Veerati, P.C.; Gosens, R.; Bartlett, N.W.; Wark, P.A.; Grainge, C.L.; Stick, S.M.; Kicic, Anthony; Moheimani, F.; Hansbro, P.M.; Knight, D.A.

doi:10.1016/j.pharmthera.2017.12.009

Access Status

Fulltext not available

Authors

Reid, A.T.

Veerati, P.C.

Gosens, R.

Bartlett, N.W.

Wark, P.A.

Grainge, C.L.

Stick, S.M.

Kicic, Anthony

Moheimani, F.

Hansbro, P.M.

Knight, D.A.

Date

2018

Type

Journal Article

Metadata

Show full item record

Citation

Reid, A.T. and Veerati, P.C. and Gosens, R. and Bartlett, N.W. and Wark, P.A. and Grainge, C.L. and Stick, S.M. et al. 2018. Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches. Pharmacology and Therapeutics. 185: pp. 155-169.

Source Title

Pharmacology and Therapeutics

DOI

10.1016/j.pharmthera.2017.12.009

ISSN

0163-7258

Faculty

Faculty of Health Sciences

School

School of Public Health

URI

http://hdl.handle.net/20.500.11937/76808

Collection

Curtin Research Publications

Abstract

© 2017 Dysregulated induction of goblet cell differentiation results in excessive production and retention of mucus and is a common feature of several chronic airways diseases. To date, therapeutic strategies to reduce mucus accumulation have focused primarily on altering the properties of the mucus itself, or have aimed to limit the production of mucus-stimulating cytokines. Here we review the current knowledge of key molecular pathways that are dysregulated during persistent goblet cell differentiation and highlights both pre-existing and novel therapeutic strategies to combat this pathology.